Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Rating of “Buy” by Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have earned an average recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $16.5556.

IVA has been the topic of a number of research analyst reports. Wall Street Zen lowered Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. HC Wainwright set a $24.00 price target on Inventiva and gave the stock a “buy” rating in a research note on Wednesday, January 28th. UBS Group initiated coverage on Inventiva in a research note on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price target on the stock. Barclays initiated coverage on Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target on the stock. Finally, Truist Financial initiated coverage on Inventiva in a research note on Thursday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock.

Inventiva Stock Up 4.2%

IVA opened at $5.74 on Thursday. Inventiva has a 52 week low of $2.85 and a 52 week high of $7.98. The business’s fifty day simple moving average is $6.01 and its 200 day simple moving average is $5.36.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million during the quarter. On average, equities analysts expect that Inventiva will post -2.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Several hedge funds and other institutional investors have recently modified their holdings of IVA. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Inventiva by 55.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after buying an additional 9,212 shares during the period. Creative Planning purchased a new stake in shares of Inventiva during the 2nd quarter valued at about $32,000. Commonwealth Equity Services LLC raised its holdings in shares of Inventiva by 19.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after buying an additional 12,704 shares during the period. Virtu Financial LLC purchased a new stake in shares of Inventiva during the 4th quarter valued at about $60,000. Finally, XTX Topco Ltd purchased a new stake in shares of Inventiva during the 4th quarter valued at about $84,000. 19.06% of the stock is owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.